在小鼠中,水溶性vidarabine衍生物可以缓解由catecholamine引起的心力衰竭和心律失常,而不会损害心脏功能
Kenji Suita1, Yoshio Hayakawa1,2, Yujiro Hoshino3
1Department of Physiology, Tsurumi University School of Dental Medicine, Yokohama, Japan.
PloS one
|August 20, 2025
概括
新的维达拉宾衍生物为心力衰竭 (HF) 治疗提供了更好的溶解性. 这些化合物有效地抑制心脏腺环酶 (AC) 活性,减轻心脏衰竭的进展和心律失常,而不会影响心脏功能.
科学领域:
- 心血管药理学
- 药物发现
- 分子心脏病学
背景情况:
- 标准心力衰竭 (HF) 治疗的向是同情神经系统,但有些患者不能耐受β-上腺素受体 (β-AR) 阻断剂.
- 乙环酶 (AC) 异形特异性治疗为治疗HF提供了替代方法.
- 视达拉宾选择性地抑制心脏交流,在临床前的HF模型中显示有希望,对心脏功能没有不良影响.
研究的目的:
- 开发具有增强水溶性和保持治疗活性的新型维达拉宾衍生物.
- 为了克服维达拉宾溶解度不佳的局限性,需要长时间,大量的静脉注射.
主要方法:
- 通过用 (二甲基胺) 乙烯基组修改阿拉比诺斯环来合成维达拉宾衍生物 (V2E,V3E,V5E).
- 在体外评估衍生物对心脏交流活性的抑制作用.
- 在小鼠模型中对衍生品在改善HF和降低心房的疗效进行了体内评估.
主要成果:
- 与维达拉宾相比,V2E,V3E和V5E的水溶性显著改善.
- 这些新衍生药物表现出与vidarabine可比的心脏AC抑制活性.
- 在小鼠中,使用V2E,V3E和V5E有效地改善了HF的发展,并降低了对心房的敏感性.
结论:
- 维达拉宾衍生物 (V2E,V3E,V5E) 是对心力衰竭的一种有前途的治疗策略.
- 这些衍生品具有更好的药物动力学特性,可能使得更少的侵入性施用途径成为可能.
- 这些化合物的增强溶解性和维持有效性需要进一步研究在HF治疗中的临床应用.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
847
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
847
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23